Akari Therapeutics PLC (AKTX)
2.42
-0.36
(-12.95%)
USD |
NASDAQ |
Nov 04, 16:00
2.42
0.00 (0.00%)
After-Hours: 16:42
Akari Therapeutics Research and Development Expense (Annual): 5.45M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.45M |
| December 31, 2022 | 9.561M |
| December 31, 2021 | 9.134M |
| December 31, 2020 | 8.820M |
| December 31, 2019 | 8.739M |
| December 31, 2018 | 11.80M |
| December 31, 2017 | 23.29M |
| Date | Value |
|---|---|
| December 31, 2016 | 17.31M |
| December 31, 2015 | 5.799M |
| December 31, 2014 | 1.616M |
| December 31, 2013 | 1.276M |
| December 31, 2012 | 1.483M |
| December 31, 2011 | 0.841M |
| December 31, 2010 | 0.247M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.45M
Minimum
2023
9.561M
Maximum
2022
8.341M
Average
8.820M
Median
2020
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 60.22M |
| Cellectis SA | 87.65M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 31.19M |